Clinical trials: Temozolomide, completed
Glioblastoma
Anticancer Therapeutic Vaccination Using Telomerase-derived Universal Cancer Peptides in Glioblastoma
Glioblastoma (GBM) is the most frequent primary brain tumor and the brain tumor with the poorest prognosis. The current treatment relies on surgical resection of gross tumor followed by radiochemotherapy and adjuvant therapy with…
- Trial name
- UCPVax-Glio (NCT04280848)
- Testing
- UCPVax, Temozolomide
- Where
- 5 sites in France
- Volunteers
- 67 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Brain and Central Nervous System Tumors
Radiation Therapy (RT) and Temozolomide (TMZ) in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them…
- Trial name
- NCT00304031
- Testing
- Concurrent temozolomide, Concurrent radiation therapy, 100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle
- Where
- 351 sites in United States, Canada
- Volunteers
- 1,173 people
- Sponsor
- Radiation Therapy Oncology Group
Adult Giant Cell Glioblastoma, Adult Glioblastoma
MRI and PET/FMISO In Assessing Tumor Hypoxia in Patients With Newly Diagnosed Glioblastoma Multiforme
This phase II trial is studying how well positron emission tomography (PET) scan using 18F-fluoromisonidazole works when given together with magnetic resonance imaging (MRI) ) in assessing tumor hypoxia in patients with newly…
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma
- Trial name
- NCT00902577
- Testing
- FMISO, MRI, PET
- Where
- 14 sites in United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Glioblastoma, Gliosarcoma
Ph II Bev + Either Temozolomide/Etoposide for GBM Pts Who Have Failed Bev + Irinotecan
Primary objective To estimate 6-month progression free survival probability of pts w recurrent GBM treated w bev + either daily temozolomide/etoposide following progression on bev + irinotecan Secondary Objectives To evaluate…
- Trial name
- NCT00613028
- Testing
- Temo + Avastin, VP-16 + Avastin
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Duke University
Brain Neoplasms, Malignant, Primary
Bioequivalence Study of Temozolomide in Patients With Primary Tumors of the Central Nervous System
The purpose of this crossover, single-dose, bioequivalence study is to compare the rate and extent of absorption of Temozolomide after the administration of the study product (Dralitem®, Monte Verde S.A.) and the reference…
- Trial name
- NCT02343081
- Testing
- Temozolomide
- Where
- 2 sites in Argentina
- Volunteers
- 24 people
- Sponsor
- Monte Verde SA
Metastatic Cancer
Temozolomide and Vinorelbine in Treating Patients With Recurrent Brain Metastases
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I/II trial to study the effectiveness of temozolomide and vinorelbine in treating patients who…
- Trial name
- NCT00026494
- Testing
- temozolomide, vinorelbine tartrate
- Where
- 2 sites in United States
- Volunteers
- 49 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Brain and Central Nervous System Tumors
Bevacizumab and Erlotinib After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00720356
- Testing
- bevacizumab, erlotinib hydrochloride
- Where
- 9 sites in United States
- Volunteers
- 115 people
- Sponsor
- Northwestern University
Glioblastoma
A Study of BBI608 in Combination With Temozolomide in Adult Patients With Recurrent or Progressed Glioblastoma
This is an open label, multi-center, phase 1 safety run-in and phase 2 study of BBI608 in combination with temozolomide in patients with recurrent or progressive glioblastoma who have not received prior bevacizumab therapy.
- Trial name
- NCT02315534
- Testing
- BBI608, Temozolomide
- Where
- 3 sites in United States, Canada
- Volunteers
- 34 people
- Sponsor
- Sumitomo Pharma America, Inc.
Leukemia, Myeloid
Phase 2 Study of Temozolomide to Treat Poor Risk / Refractory Acute Myeloid Leukemia
Open-label, non-randomized, parallel assignment, phase 2 trial assessing the safety and efficacy of distinct temozolomide treatment regimens for patients with AML and poor prognosis
- Trial name
- NCT00611247
- Testing
- Temozolomide
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Bruno C. Medeiros
Medulloblastoma
A Phase II Study of Oral LDE225 in Patients With Hedge-Hog (Hh)-Pathway Activated Relapsed Medulloblastoma (MB)
This Phase II study evaluated the safety and efficacy of LDE225 in adult and pediatric patients with Hh-pathway activated, relapsed MB.
- Trial name
- NCT01708174
- Testing
- LDE225, TMZ
- Where
- 41 sites in United States, Australia and 11 more
- Volunteers
- 22 people
- Sponsor
- Novartis Pharmaceuticals
Glioblastoma Multiforme, Glioma
Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors
In this study, investigators will conduct a phase I/II trial in recurrent (temozolomide resistant) glioma patients. The overall goal of this study is to provide a foundation for future studies with indoximod tested in newly…
- Conditions
- Glioblastoma Multiforme, Glioma, Gliosarcoma, Malignant Brain Tumor
- Trial name
- NCT02052648
- Testing
- Indoximod, Temozolomide, Bevacizumab
- Where
- 17 sites in United States
- Volunteers
- 160 people
- Sponsor
- NewLink Genetics Corporation
Glioblastoma, GBM
A Phase I Trial of High-Dose Ascorbate in Glioblastoma Multiforme
This is a phase 1 (first in man) study testing the safety of adding high dose ascorbate (vitamin C) to standard radiation and chemotherapy for initial treatment of glioblastoma multiforme (GBM).
- Conditions
- Glioblastoma, GBM, Glioblastoma Multiforme
- Trial name
- NCT01752491
- Testing
- Ascorbate, Temozolomide, Radiation therapy
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Joseph J. Cullen, MD, FACS
Nausea, Vomiting
Emend and Ondansetron Compared to Ondansetron Alone to Prevent CINV in Glioma Patients Receiving Temozolomide
Patients diagnosed with malignant glioma who are receiving temozolomide will be accrued in this open label, phase 2, randomized single institution trial of aprepitant in combination with ondansetron versus ondansetron alone for…
- Conditions
- Nausea, Vomiting, Glioma
- Trial name
- NCT01450826
- Testing
- aprepitant, ondansetron
- Where
- United States
- Volunteers
- 136 people
- Sponsor
- Katy Peters
Ewing Sarcoma, Rhabdomyosarcoma
Phase I Study of Olaparib and Temozolomide for Ewings Sarcoma or Rhabdoomyosarcoma
This research study is a Three arm Phase I clinical trial, which tests the safety of an investigational drug or combination of drugs and also tries to define the appropriate dose of the combination of investigational drugs to use…
- Trial name
- NCT01858168
- Testing
- Olaparib, Temozolomide, Irinotecan
- Where
- 5 sites in United States
- Volunteers
- 49 people
- Sponsor
- Massachusetts General Hospital
Glioblastoma Multiforme
Phase II Feasibility Study of Dendritic Cell Vaccination for Newly Diagnosed Glioblastoma Multiforme
Adult patients who have surgical resection of newly diagnosed glioblastoma multiforme will be treated with radiotherapy/chemotherapy followed by dendritic cell vaccine.
- Trial name
- NCT00323115
- Testing
- Autologous Dendritic Cell, Temozolomide, Radiotherapy
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Recurrence of Solid Tumor, Glioblastoma Multiforme
Study of the Safety and Efficacy of MK-4827 Given With Temozolomide in Participants With Advanced Cancer (MK-4827-014 AM1)
This is a non-randomized two-part study of MK-4827 given with temozolomide in participants with advanced cancer. In Part A of the study, the dose-limiting toxicities (DLTs) and the maximum tolerated dose (MTD) of MK-4827 when…
- Conditions
- Recurrence of Solid Tumor, Glioblastoma Multiforme, Melanoma
- Trial name
- NCT01294735
- Testing
- MK-4827, Temozolomide
- Volunteers
- 19 people
- Sponsor
- Merck Sharp & Dohme LLC
Metastatic Cancer
Temozolomide in Treating Patients With Solid Tumors That Have Spread to the Brain
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of temozolomide in treating patients who have advanced…
- Trial name
- NCT00012116
- Testing
- temozolomide
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Newly-diagnosed Glioblastoma
Angiotensin II Receptor Blockers, Steroids and Radiotherapy in Glioblastoma
To assess the efficacy of an Angiotensin-II inhibitor (Losartan) to reduce peritumoral edema in newly diagnosed glioblastoma patients.
- Trial name
- ASTER (NCT01805453)
- Testing
- Losartan
- Where
- France
- Volunteers
- 80 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Adult Giant Cell Glioblastoma, Adult Glioblastoma
Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
This phase I/II trial studies the side effects and best dose of vorinostat when given together with temozolomide and radiation therapy and to see how well they work in treating patients with newly diagnosed glioblastoma…
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma
- Trial name
- NCT00731731
- Testing
- 3-Dimensional Conformal Radiation Therapy, Cognitive Assessment, Laboratory Biomarker Analysis
- Where
- 110 sites in United States
- Volunteers
- 125 people
- Sponsor
- National Cancer Institute (NCI)
Gliosarcoma, Glioblastoma
PH I Addition of Farnesyl Transferase Inhibitor to Temozolomide for Pts w Gr 3 & 4 Malignant Gliomas
Objectives: To determine maximum tolerated dose of farnesyl transferase inhibitor, SCH 66336, when administered w TEMODAR®. To characterize any toxicity associated w combo of farnesyl transferase inhibitor, SCH 66336, \&…
- Conditions
- Gliosarcoma, Glioblastoma, Anaplastic Astrocytoma
- Trial name
- NCT00612651
- Testing
- Temodar and SCH 66336
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Duke University